- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 592KB)
Enzalutamide – March 2023
Enzalutamide: Capsule 40 mg; Xtandi®
Last updated
30 June 2023